COSCIENS Biopharma Inc. - Form 6-K Filing

COSCIENS Biopharma Inc. filed a preliminary management proxy circular on April 20, 2026, for its annual general and special meeting of shareholders in June 2026. The key proposal is a share consolidation and subsequent split, aiming to reduce the number of shareholders to below 300, thereby enabling the company to suspend its SEC reporting obligations by filing a Form 15. Shareholders holding fewer shares than the consolidation ratio will receive a cash payment of $1.60 per share. The company believes this move will reduce costs associated with SEC reporting while maintaining its status as a reporting issuer in Canada. The board of directors unanimously recommends voting in favor of this share capital amendment, which is considered a "going-private transaction." The consolidation consideration is deemed fair by Segal Valuation and Transaction Advisory LP. The meeting will also cover the election of directors, appointment of auditors (Deloitte LLP), and presentation of the 2025 financial statements.